Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 13,442

Document Document Title
WO/2018/220355A1
The present invention relates to a class of sulfonamide-substituted cyanopyrrolidines of Formula (Ia) and (Ib) with activity as inhibitors of deubiquitilating enzymes, in particular, ubiquitin C-terminal hydrolase L1 (UCHL1) and ubiquiti...  
WO/2018/220542A1
The present invention relates to compounds having structural formula (I) wherein R1 and R2 are defined as set forth in the description. The invention also relates to a process for the manufacture of the above compounds of formula (I), wh...  
WO/2018/220365A1
The invention relates to antibiotic compounds of formula (A1) and pharmaceutically acceptable salts, solvates, tautomers and combinations thereof, wherein X and L are optional linkers and one of RA or R1 comprises Ar1, wherein Ar1 is an ...  
WO/2018/222169A2
Disclosed are vanadyl complexes of Formula 1, Formula 2, and Formula 3, wherein Ri, R2, and R are defined as in the description. The pharmaceutical compositions containing these complexes and uses of the complexes for treatment of Diabet...  
WO/2018/217050A1
The present invention relates to: a novel method for preparing a heterocyclic derivative compound of chemical formula I below; a novel intermediate compound used in the preparation method; a composition for treatment or prevention of hyp...  
WO/2018/216800A1
The present invention provides: a compound represented by general formula (I) or a salt thereof; an LSD1 inhibitor which contains the compound or a salt thereof as an active ingredient; a pharmaceutical composition which contains the com...  
WO/2018/214686A1
The present invention discloses a method for preparing an isoxazinone compound (I) and an application thereof. The method and the application thereof comprise: reacting a compound (II) and carboxylic acid (III) under the action of a dehy...  
WO/2018/215318A1
The invention relates to heteroaromatic compounds, particularly for use in electronic devices. The invention further relates to a method for producing the compounds according to the invention and to electronic devices containing same.  
WO/2018/215668A1
The invention relates to novel inhibitors of MAP4K1 (HPK1) useful for the treatment of diseases or disorders characterised by dysregulation of the signal transduction pathways associated with MAPK activation, including hyperproliferative...  
WO/2018/213422A1
The present invention features compounds useful in the treatment of BAF complex related disorders.  
WO/2018/205038A1
Pharmaceutical compositions comprising a mixture of cannabinoids and terpenes and use thereof in the treatment of select disorders mediated by the Hedgehog (HH) signaling pathway are disclosed. In preferred embodiments, the components of...  
WO/2018/206539A1
The specification relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them an...  
WO/2018/202733A1
The present disclosure is directed to an improved process to convert crude ascomycin to purified pimecrolimus. Crude ascomycin is chlorinated with triphenylphosphine and N-chlorosuccinimide (NCS) to yield crude pimecrolimus, which is the...  
WO/2018/203302A1
This invention is in the field of medicinal chemistry and relates to compounds, and pharmaceutical compositions thereof that are useful as antibacterial agents. The compounds are useful as inhibitors of bacterial gyrase activity and of b...  
WO/2018/204416A1
The present disclosure relates to rapamycin analogs of the general Formula (I). The compounds are inhibitors of mTOR and thus useful for the treatment of cancer, immune-mediated diseases and age related conditions.  
WO/2018/203298A1
The present application relates to substituted fused heteroaryl and heterocyclic compounds, useful as nicotinamide adenine dinucleotide phosphate oxidase inhibitors (NADPH oxidase inhibitors), processes for their preparation, pharmaceuti...  
WO/2018/197653A1
The present invention relates to crystalline polymorph forms of (5)-2-((2-((5)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6- dihydrobenzo[ƒ]imidazo[ 1,2-J] [ 1,4]oxazepin-9-yl)amino)propanamide (GDC-0077), having the structure, Formula ...  
WO/2018/197447A1
The present invention relates to bridged triarylamines which correspond to a defined formula. Said compounds are suitable for use in electronic devices. The invention also relates to methods for preparing said compounds and to electronic...  
WO/2018/199699A1
The present specification provides a heterocyclic compound of chemical formula 1 and an organic light emitting element comprising the same.  
WO/2018/195321A1
Compounds according to formula (I), methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.  
WO/2018/184196A1
Provided are a method for preparing 2-arylmalonamide and applications of the method. The method uses 2-(cyclohexylene) malononitrile as raw material that undergoes an aromatization-hydrolysis reaction under the effects of an oxidizer and...  
WO/2018/187553A1
Disclosed are compounds of Formula 1, including all geometric and stereoisomers, tautomers, N-oxides, and salts thereof, wherein R1, L and J are as defined in the disclosure. Also disclosed are compositions containing the compounds of Fo...  
WO/2018/177302A1
Disclosed are a nitrogen containing heterocycle substituted benzoxazine oxazolidinone compound, a preparation method thereof and the use in the preparation of a drug for treating and/or preventing infectious diseases induced by Mycobacte...  
WO/2018/181883A1
The purpose of the present invention is to provide: a compound having anti-HBV activity or a salt thereof; a pharmaceutical composition; an anti-hepatitis B virus agent; a DNA generation inhibitor of a hepatitis B virus; and a hepatitis ...  
WO/2018/183418A1
Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula (I), or a ste...  
WO/2018/178777A1
The present invention relates to an improved process for the preparation Crystalline Form G2 of Rifaximin of Formula (I). The invention also relates to crystalline Form G2 of Rifaximin (I) obtained by the process of the present invention...  
WO/2018/177899A1
The present invention relates to novel modified macrocyclic compounds with improved tolerability of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of...  
WO/2018/183964A1
Isoquinoline compounds and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1 -dependent disorders and enhancing an immune response. Also described are methods of inhibiting ...  
WO/2018/177889A1
The present invention relates to novel modified macrocyclic compounds with improved tolerability of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of...  
WO/2018/172984A1
This invention relates to certain novel pyrazine derivatives (Formula I) as SHP2 inhibitors which is shown as formula I, their synthesis and their use for treating a SHP2 mediated disorder. More particularly, this invention is directed t...  
WO/2018/166934A1
The present invention relates to dibenzofuran and dibenzothiophene derivatives, in particular for use as triplet matrix materials in organic electroluminescent devices. The invention further relates to a method for producing the compound...  
WO/2018/168818A1
The present invention relates to tetrahydroquinoline derivatives of the present invention or a pharmaceutically acceptable salt thereof or a prodrug thereof, processes for their preparation, pharmaceutical compositions containing them an...  
WO/2018/165760A1
The present disclosure relates generally to antioxidants. More particularly, the present disclosure relates to lubricating compositions comprising an antioxidant.  
WO/2018/167695A1
The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof. It further discloses a pharmaceutical composition comprising the compounds of Formula (I) and their uses, in particular t...  
WO/2018/167113A1
The invention provides novel compounds having the general formulas (I), (II), wherein R1, R2, Y, W, A, X, m and n are as defined herein, compositions including the compounds and methods of using the compounds.  
WO/2018/167690A1
The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof: It further discloses a pharmaceutical composition comprising the compounds of Formula (I) and their uses, in particular t...  
WO/2018/167276A1
The present invention relates to compounds of Formula (I) as defined herein, and salts, hydrates and solvates thereof. The present invention also relates to pharmaceutical compositions comprising compounds of Formula (I), and to the use ...  
WO/2018/164191A1
The present invention provides a substituted pyrrolidine compound having orexin receptor type 2 agonist activity. A compound represented by the formula (in the formula, each symbol is as described in the specification) or a salt thereof ...  
WO/2018/165071A1
The present disclosure relates to solid state forms of Midostaurin, processes for preparation thereof, pharmaceutical compositions thereof, and use thereof in the treatment of Acute Myelogenous Leukemia (AML) and Aggressive Systemic Mast...  
WO/2018/162443A1
The present invention relates to tricyclic inhibitors of beta-secretase having the structure shown in Formula (I) and (II) and the tautomers and the stereoisomeric forms thereof, wherein the radicals are as defined in the specification. ...  
WO/2018/161960A1
10-oxo-6,1-dihydrobenzo[e]pyrido[1,2-c][1,3]oxazine-9-carbox ylic acid derivatives of formula (I) as hepatitis B surface antigen inhibitors or pharmaceutically acceptable salts thereof, and uses of a compound of formula (I) or pharmaceut...  
WO/2018/160892A1
Macrocyclic Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, Formula IV, Formula V,...  
WO/2018/158646A1
The present invention relates to a process for the preparation of crystalline Form GR of Rifaximin (I). The invention also relates to crystalline Form GR of Rifaximin obtained by the process of the present invention, the said Form GR bei...  
WO/2018/160003A1
The present specification relates to a heterocyclic compound of chemical formula 1 and an organic light-emitting device comprising same.  
WO/2018/155275A1
Provided is an oxygen-bridged triphenylamine compound that is suitable for a light-emitting material of an organic electroluminescent element. The compound is represented by formula (1) [wherein ring A, ring B and ring C independently re...  
WO/2018/153507A1
Compounds of formula (I), wherein R', R'', R, X, W, Q, n and m have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.  
WO/2018/149608A1
The present invention relates to crystalline forms of cabotegravir sodium and to methods for their preparation. Furthermore, the invention relates to a pharmaceutical composition comprising one of said crystalline forms of cabotegravir s...  
WO/2018/148204A1
Provided are compounds of Formulas (I'), (I), (II') and (II), or pharmaceutically acceptable salts thereof, and methods for their use and production.  
WO/2018/141854A1
The present invention provides piperazine derivatives exhibiting high affinity to the stem region (viral membrane proximal part) of influenza hemagglutinin as determined through competition binding and high virus neutralization activity ...  
WO/2018/144605A1
The present disclosure generally relates to compounds and pharmaceutical compositions which may be used in methods of treating a hepatitis B virus infection.  

Matches 1 - 50 out of 13,442